ClinicalTrials.gg
RecruitingNCT06180551RESCUE-AKIUpdated Dec 22, 2023

Homburg Renal Evaluation Study on the Clinical Utility of Early AKI Diagnosis

An observational study in Acute Kidney Injury, sponsored by Universität des Saarlandes. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-22.

Sponsored by Universität des Saarlandes · Observational

How we know

From the registry’s dates

  • Started Dec 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
1,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 109 studies in Acute Kidney Injury with a site in Germany — 21 open to participants now, 24 under way, 1 of them phase 3. Acute Kidney Injury · Germany.

Planned enrollment
6th of 47
1,000 · median 120
Started
2023
with 8 others
Observational
47 of 109
7 open now
Primary completion
2026-12
later than 9 of 23 live
Registered
88th of 109
by date

Among the 109 studies in Acute Kidney Injury with a site in Germany, this one is the 6th largest by planned enrollment of the 47 observational ones that give a count, is one of 9 that started in 2023, is one of 47 observational ones, reaches primary completion later than 9 of the 23 other live ones, and was the 88th registered.

Acute Kidney Injury

1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.

Browse Acute Kidney Injury studies →

Open to participants now

21 of the 109 studies in Acute Kidney Injury with a site in Germany are open now. Recruiting first, the newest first:

15 more — sign in →

All 21 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 109 studies in Acute Kidney Injury with a site in Germany, or all of them as a file.
02

Study summary

Critically ill patients are at risk of developing a sudden decrease of kidney function which may be detected by a decrease in urine output or is diagnosed on the basis of blood tests for substances normally eliminated by the kidney, primarily creatinine.

Because it takes about 24 hours for the creatinine level to rise, even if both kidneys have ceased to function, better markers are needed.

This trial is investigating if the marker urinary dickkopf-3 (uDKK3) allows an early prediction of a sudden decrease of kidney function.

Read the detailed description

Urinary dickkopf-3 (uDKK3), a stress-induced renal tubular epithelium-derived glycoprotein, has been identified as a biomarker predicting persistent kidney dysfunction.

In this prospective observational trial in patients at high risk of developing acute kidney injury we will assess whether urinary dickkopf-3 serves as a predictor of acute kidney injury.

Patients of the intensive care units of Saarland University Hospital will be surveyed for up to two years after their admission to the intensive care unit.

The progression of the estimated Glomerular Filtration Rate and uDKK3 will be monitored.

03

Conditions studied

  • Acute Kidney Injury

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Patients on intensive care units of the Saarland University Hospital.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients treated on the intensive care units of Saarland University Hospital.

Exclusion criteria

Exclusion Criteria:

  • Patients on renal replacement treatment before admission to the intensive care unit.
  • Patients with chronic kidney disease stage CKD G3b or below.
  • Known kidney disease.
  • Kidney transplantation.
  • Intoxications leading to dialysis treatment.
  • Participation in other clinical trials.
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Target follow-up
2 Years
Patient registry
Yes
Biospecimen retention
Samples without dna

Interventions

  • Diagnostic testDKK-3

    DKK-3-Urine measurement

06

What researchers measure

Primary outcomes

  1. Urinary dickkopf-3

    Urinary dickkopf-3

    Time frame: Throughout observational period, defined as timeframe from admission to intensive care unit up to two years after.

  2. Estimated Glomerula Filtration Rate

    Estimated Glomerula Filtration Rate by CKD-EPI-formula.

    Time frame: Throughout observational period, defined as timeframe from admission to intensive care unit up to two years after.

Secondary outcomes

  1. Mortality

    Number of patients who die during the observational period.

    Time frame: Throughout observational period, defined as timeframe from admission to intensive care unit up to two years after.

  2. End Stage Renal Disease

    Number of patients with initiation of chronic kidney replacement therapy (maintenance dialysis or kidney transplantation).

    Time frame: Throughout observational period, defined as timeframe from admission to intensive care unit up to two years after.

  3. Length of renal replacement therapy

    Length of time patients receive renal replacement therapy for chronic kidney injury.

    Time frame: During the ICU stay.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Dec 2026, 36 months after the start.

Of 350 non-industry observational studies under Acute Kidney Injury, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's planned 36 months is above that.

Counting every sponsor, half of 365 studies reached it within 24 months; a quarter within 12 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2023
First posted
Dec 22, 2023
StartActual
Dec 1, 2023
Primary completionEst.
Dec 2026
CompletionEst.
Jun 2027
Last update
Dec 22, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06180551
Lead sponsor
Universität des Saarlandes
Responsible party
Sponsor
First posted
Dec 22, 2023
Start date
Dec 1, 2023
Primary completion
Dec 2026 (estimated)
Completion
Jun 2027 (estimated)
Last update
Dec 22, 2023

Study contacts

Stefan Neuhaus, MD
Contact
stefan.neuhaus@uks.eu
+4968411615041
Stefan Neuhaus, MD
principal investigator · Universität des Saarlandes

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion